Return to Drug Transparency Home Page:

LC-DT Home

Subscribe/Unsubscribe to LISTSERV email notifications for Nevada Drug Transparency Information and Updates Here: 

 Subscribe to Drug Transparency LISTSERV                     Unsubscribe to Drug Transparency LISTSERV

Drug Transparency - Essential Lists, Reports & Resources

Previously, DHHS extended the April 1st reporting deadline due to COVID-19. Due to this extension, DHHS will be delaying the posting of the June 1st report as we want to provide the most accurate and complete report possible. We apologize for the delay and will update this page with the new deadline date when it is available.

Essential Diabetes and Asthma Drug List ~ NRS 439B.630

Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to compile a list of prescription drugs that the Department determines to be essential for treating diabetes in this State and the wholesale acquisition cost of each drug on the list. Effective May 30, 2019, Senate Bill No. 262 builds on Nevada’s diabetes drug pricing transparency law by including asthma drugs. The list must include, without limitation, all forms of insulin and biguanides marketed for sale in this State.

2020 Essential Diabetes and Asthma Drug List v03.24.2020

Supersedes 02/01/2020 version

Drug Pricing Report ~NRS 439B.635

Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to analyze the information submitted pursuant to sections 3.8, 4 and 4.2 of this act and compile a report on the price of the prescription drugs that appear on the most current lists compiled by the Department pursant to section 3.6 of this act, the reasons for any increase in those prices and the effect of those prices on overall spending on prescription drugs in the State. The report may include, without limitation, opportunities for persons and entities in this State to lower the cost of drugs for the treatment of diabetes while maintaining access to such drugs.

Supplemental Report ~ 2017 Essential Diabetes Drugs

DHHS received drug manufacturer and PBM reports specific to the 2017 Essential Diabetes Drugs and prepared this report as a supplement to the reports published in 2018.

Essential Diabetes Drugs Price Increase Report

Essential Diabetes Drugs Prices Increase Report – September 11, 2018. This 2018 report of essential medications reflects those drugs that showed a price increase above the thresholds established in the law.

Analysis of Essential Diabetes Drugs that had a Price Increase

Analysis of Essential Diabetes Drugs that had a Price Increase - September 30, 2018

Pharmaceutical Sales Representatives Report ~ NRS 439B.660

Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to compile a report on the activities of pharmaceutical sales representatives in this state with a list of prescription drugs used to treat diabetes and requiring each pharmaceutical sales representative to report samples as well as compensation in excess of $10 provided to health care providers within the State of Nevada.

Compensation and Samples Distributed by Pharmaceutical Sales Representatives in Nevada v06.01.2018

Drug Transparency Statutes and Regulations

Nevada Revised Statutes ~ Chapter 439B

The Nevada Revised Statutes (NRS) are all the current codified laws of the State of Nevada. Nevada law consists of the Constitution of Nevada (the state constitution) and Nevada Revised Statutes.

Nevada Administrative Code ~ Chapter 439

The Nevada Administrative Code (NAC) are all the current codified regulations for the State of Nevada